查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870891

克隆氏症治疗市场：2025-2032年全球预测（依治疗方法、给药途径、通路和最终用户划分）

Crohn's Disease Therapeutics Market by Therapy Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，克隆氏症治疗市场将成长至 209.2 亿美元，复合年增长率为 5.76%。

关键市场统计数据
基准年 2024 133.6亿美元
预计年份：2025年 141.3亿美元
预测年份 2032 209.2亿美元
复合年增长率 (%) 5.76%

全面介绍克隆氏症药物市场：重点关注临床驱动因素、未满足的需求和不断发展的治疗模式

克隆氏症仍然是一种复杂多样的发炎性肠道疾病，对临床医生、支付方和生命科学创新者都构成了挑战。过去十年，治疗方法已从广泛的免疫抑制疗法转向生物目标和小分子药物策略，旨在调节特定的免疫路径。因此，在治疗决策中，平衡疗效与以病人为中心的考量因素（例如长期安全性、免疫抗原性、给药途径和治疗负担）变得越来越重要。因此，相关人员必须应对这样一种局面：临床疗效、便利性和安全性共同影响着药物的接受度和病人的依从性。

变革性转变重塑克隆氏症治疗：新型作用机制、成功的临床试验、以病人为中心的服务模式与支付方趋势

克隆氏症治疗格局正在经历变革，这主要得益于生物特异性的提升、口服小分子药物的出现以及以患者为中心的医疗服务模式的日益普及。新型作用机制，例如更具选择性的白细胞介素和整合素阻断剂，正在改变人们对持久缓解和黏膜癒合的预期，而真实世界研究证据也进一步明确了这些药物相对于传统药物的定位。同时，製剂和给药方式的创新也拓展了治疗选择，提供了更方便的皮下和口服方案，从而减轻了患者的治疗负担。

评估美国2025年实施的累积关税对治疗药物供应链、定价策略、临床应用和创新奖励的累积影响

美国将于2025年生效的累积关税将为治疗药物供应链、商业性定价策略和广泛进入机制创造新的营运环境。关税导致的投入成本上涨，例如活性成分、生物製药、管瓶和辅助耗材，可能会增加生产和分销成本。为此，製造商可能会重新评估其海外供应集中度，加速本地生产投资，或调整筹资策略以降低关税波动带来的影响。

透过细分市场分析，深入了解治疗层级、给药途径、分销管道和最终用户路径对结果和商业策略的影响。

对克隆氏症药物进行细分市场分析，揭示了治疗层级、给药途径、分销管道和最终用户如何共同影响临床和商业性结果。基于治疗方法类别，市场可细分为生物製药、免疫抑制剂和小分子药物，生物製药内部仍可进一步细分。具体类别包括整合素抑制剂（如维多珠单抗）、白细胞介素抑制剂（如利沙珠单抗和Ustekinumab单抗）以及TNF抑制剂（如Adalimumab、赛妥珠单抗和Infliximab）。免疫抑制剂通常为胺基甲基叶酸和硫嘌呤类药物（包括Azathioprine和Mercaptopurine），而小分子药物则以JAK抑制剂为主，主要是託法替尼和Upadacitinib，它们具有不同的监管和安全性特征。

美洲、欧洲、中东和非洲以及亚太地区治疗方案采纳、法规结构、取得途径和商业性动态的区域观点

区域趋势对于治疗创新如何惠及患者以及如何在不同医疗体系中执行商业策略至关重要。美洲市场的特点是支付方结构分散、专科药房网络强大，以及高度成熟的商业性模式，这些都有利于差异化的价值提案和基于绩效的合约。同时，欧洲、中东和非洲地区（EMEA）的特点是监管和报销环境复杂多样，包括集中核准系统、国家层面的准入谈判以及不同的卫生技术评估（HTA）实践。这就要求制定适应性强的市场进入策略，并进行强有力的本地证据收集工作。

主要企业层级深入检验克隆氏症治疗领域的竞争定位、开发平臺、策略联盟、生产规模和市场差异化策略。

公司层级针对克隆氏症治疗的策略反映了产品组合多元化、定向研发投资和商业性合作的综合策略。领先的生物製药公司专注于差异化的作用机制，例如选择性白细胞介素调节和肠道特异性整合素阻断，同时投资于生命週期策略，例如适应症拓展、製剂替代和联合治疗。同时，中型市场和专业生物技术公司则透过生物标记驱动的研发和精准医疗方法，寻求利基市场定位，以满足未被满足需求的患者群体。

为指导克隆氏症药物的临床开发、商业性实施、病患取得和供应保障，提出实际的优先建议

克隆氏症病领域的领导企业应采取一系列优先行动，协调临床开发、商业性执行和病患可及性这三大关键要素。首先，设计临床计画时，应将可靠的疗效终点与可操作的真实世界数据结合，以满足监管机构、付款者和临床医生的需求。这种双重关注有助于将克罗恩病纳入治疗流程的优先顺序。其次，透过地理多元化和合约弹性优化供应链，以减轻关税和地缘政治动盪的影响，并确保慢性病患者治疗的连续性。

一项综合性的混合方法研究途径，整合了专家访谈、系统性文献回顾、供应链检验和资料三角测量。

本执行摘要的调查方法融合了多种定性和定量方法，以确保研究结果的可靠性和可重复性。主要研究包括对临床意见领袖、支付方、专科药剂师和商业领袖进行结构化访谈，以收集关于治疗效果、推广障碍和报销趋势的真实世界观点。这些第一手研究结果辅以对同侪审查的临床文献、监管文件和指南更新的系统性回顾，以检验作用机制证据和安全性讯号。

结论整合了临床、商业性和政策方面的启示，供寻求推进治疗方案和以病人为中心的护理路径的利益相关人员参考。

总之，克隆氏症治疗领域呈现出快速的治疗创新、不断演变的医疗服务模式和不断变化的商业性格局，所有这些都要求产业和临床相关人员具备策略灵活性。虽然生物製药和口服小分子药物特异性的提高正在拓展治疗选择，但它们的推广应用将取决于其在现实世界中的疗效、可控的安全性以及是否符合支付方的预期。同时，关税政策的变化和供应链的脆弱性等外部因素也增加了营运风险，必须积极主动地加以管理。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 针对肠道菌丛的粪便微生物移植方案对克隆氏症临床治疗效果的影响
  • 口服小分子S1P受体调变器治疗中重度克隆氏症的研发与临床试验进展
  • 高成本生物製药的应用问题以及目前儿童克隆氏症症患者的保险覆盖情况
  • 利用远端数位健康平台进行个人化治疗药物监测在维持克隆氏症的新作用
  • 策略合作旨在推动克隆氏症双标靶抗整合素和抗TNF联合治疗的研发

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章克隆氏症药物市场（依治疗类别划分）

  • 生物製药
    • 整合素抑制剂
      • 维多珠单抗
    • 白细胞介素抑制剂
      • 利沙珠单抗
      • Ustekinumab
    • TNF抑制剂
      • Adalimumab
      • 赛妥珠单抗
      • Infliximab
  • 免疫抑制剂
    • 胺基甲基叶酸
    • 硫嘌呤
      • Azathioprine
      • Mercaptopurine
  • 低分子化合物
    • JAK抑制剂
      • 託法替尼
      • Upadacitinib

第九章克隆氏症药物市场依给药途径划分

  • 静脉注射
  • 口服
  • 皮下注射

第十章克隆氏症治疗药物市场（依通路划分）

  • 医院药房
  • 零售药房
  • 专科诊所

第十一章克隆氏症治疗药物市场（以最终用户划分）

  • 居家医疗环境
  • 医院
  • 专科诊所

第十二章克隆氏症治疗市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章克隆氏症治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国克隆氏症治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • AbbVie Inc.
    • Janssen Biotech, Inc.
    • Takeda Pharmaceutical Company Limited
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • Merck & Co., Inc.
    • UCB SA
    • Celltrion, Inc.
    • Samsung Bioepis Co., Ltd.
    • Sandoz International GmbH
Product Code: MRR-1A1A064C0471

The Crohn's Disease Therapeutics Market is projected to grow by USD 20.92 billion at a CAGR of 5.76% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 13.36 billion
Estimated Year [2025] USD 14.13 billion
Forecast Year [2032] USD 20.92 billion
CAGR (%) 5.76%

Comprehensive introduction to Crohn's disease therapeutics landscape emphasizing clinical drivers, unmet needs, and evolving treatment paradigms

Crohn's disease remains a complex, heterogeneous inflammatory bowel condition that challenges clinicians, payers, and life science innovators. Over the past decade therapeutic approaches have shifted from broadly immunosuppressive regimens to targeted biologic and small molecule strategies designed to modulate specific immune pathways. As a result, treatment decision-making increasingly balances efficacy with long-term safety, immunogenicity, and patient-centered considerations such as route of administration and treatment burden. Consequently, stakeholders must navigate a landscape where clinical efficacy, convenience, and safety profiles jointly influence adoption and persistence.

In parallel, healthcare systems are adapting reimbursement models, specialty pharmacy operations, and specialty clinic capabilities to support more personalized treatment algorithms. Real-world evidence initiatives and longitudinal registries are expanding understanding of treatment durability and comparative effectiveness, which in turn shape clinical guidelines and payer coverage. Given these dynamics, strategic planning for product development, market entry, and access requires integrated insights that marry clinical science with commercial realities. This executive summary synthesizes those critical dimensions to help decision-makers identify opportunities and risks within the therapeutic continuum for Crohn's disease.

Transformative shifts reshaping Crohn's disease care including novel mechanisms of action, trial successes, patient-centric delivery models, and payer dynamics

The therapeutic landscape for Crohn's disease is undergoing transformational shifts driven by advances in biological specificity, the emergence of oral small molecules, and a growing emphasis on patient-centric care delivery. Novel mechanisms of action, including more selective interleukin and integrin blockade, are changing expectations for sustained remission and mucosal healing, while real-world evidence continues to refine positioning versus legacy agents. At the same time, innovation in formulation and administration is reducing treatment burden through more convenient subcutaneous dosing and oral options that expand settings of care.

Concurrently, payers and providers are recalibrating access pathways to manage the cost and clinical complexity of newer agents. Value-based contracting, outcomes-based agreements, and specialty pharmacy integration are gaining traction as tools to align cost with observed clinical benefit. Moreover, safety signals and lifecycle management considerations are influencing label expansions and post-marketing requirements, which drive clinicians to adopt risk-management strategies. Taken together, these shifts are producing a more stratified pathway for patients where treatment selection reflects not only disease biology but also delivery preferences, safety tolerance, and system-level incentives.

Assessing the cumulative impact of United States tariffs in 2025 on therapeutics supply chains, pricing strategies, clinical access, and innovation incentives

The introduction of cumulative United States tariffs in 2025 introduces a new operating context for therapeutic supply chains, commercial pricing strategies, and broader access dynamics. Tariff-driven increases in input costs for active pharmaceutical ingredients, biologic components, vials, and ancillary supplies can raise manufacturing and distribution expenditures. In response, manufacturers may reassess offshore supply concentration, accelerate regional manufacturing investments, or revise sourcing strategies to mitigate exposure to tariff volatility.

From a commercial perspective, incremental cost pressures can complicate negotiations with payers and integrated delivery networks, prompting stronger emphasis on total cost of care and outcomes-based arrangements. In the short term, providers and specialty pharmacies may experience inventory and fulfillment stress as suppliers reorganize logistics to accommodate tariff-related constraints. Over the medium term, policy-induced cost differentials can incentivize local production, contractual hedging, and increased vertical integration among suppliers to protect margin and secure supply reliability.

Finally, the tariff environment has implications for innovation incentives. Higher trade barriers can raise the effective cost of bringing complex biologics and high-value small molecules to market in the US, thereby influencing clinical development prioritization and go-to-market sequencing. As a result, strategic planning must account for scenarios that blend procurement complexity with payer sensitivity and evolving manufacturing footprints.

Segmentation insights into how therapy classes, administration routes, distribution channels, and end-user pathways influence outcomes and commercial strategy

A segmentation-aware view of Crohn's therapeutics reveals how therapeutic class, route of administration, distribution channel, and end user jointly shape clinical and commercial outcomes. Based on therapy class, the market divides into Biologics, Immunosuppressants, and Small Molecules, with further granularity within biologics to include Integrin Inhibitors such as vedolizumab, Interleukin Inhibitors including risankizumab and ustekinumab, and TNF Inhibitors such as adalimumab, certolizumab, and infliximab. Immunosuppressants are represented by agents like methotrexate and thiopurines, the latter subgroup including azathioprine and mercaptopurine, while small molecules center on JAK inhibitors with tofacitinib and upadacitinib illustrating divergent regulatory and safety profiles.

In addition, the route of administration-intravenous, oral, and subcutaneous-meaningfully influences clinical adoption, site-of-care economics, and patient preference. Distribution channels from hospital pharmacies to retail pharmacies and specialty clinics create distinct access and dispensing models that affect continuity of care and reimbursement complexity. Finally, end users span home care settings, hospitals, and specialty clinics, each with different capabilities for monitoring, adherence support, and infusion infrastructure. When considered together, these segmentation dimensions indicate that targeted strategies must be tailored to the interplay of mechanism of action, delivery modality, channel logistics, and care setting to optimize uptake and long-term persistence.

Regional perspectives on therapeutic adoption, regulatory frameworks, access pathways, and commercial dynamics across Americas, EMEA, and Asia-Pacific

Regional dynamics are pivotal to how therapeutic innovations reach patients and how commercial strategies are executed across disparate health systems. In the Americas, markets are characterized by fragmented payer landscapes, strong specialty pharmacy networks, and a high degree of commercial sophistication that favors differentiated value propositions and outcomes-based contracting. By contrast, Europe, Middle East & Africa presents a heterogenous regulatory and reimbursement environment in which centralized approvals coexist with country-level access negotiations and diverse health technology assessment practices, requiring adaptive market access strategies and robust local evidence generation.

In the Asia-Pacific region, evolving regulatory harmonization, growing local manufacturing capabilities, and rapid adoption of digital health tools are accelerating access to both biologics and small molecules. Pricing pressures and increasing emphasis on cost-effectiveness are driving tiered launch sequencing and selective commercialization models. Across all regions, stakeholders must align clinical trial design, real-world evidence programs, and supply chain resilience to regional policy nuances and payer expectations. Ultimately, region-specific regulatory frameworks, distribution infrastructures, and patient management norms will determine the pace and shape of adoption for new Crohn's therapeutics.

Key company-level insights examining competitive positioning, R&D pipelines, strategic partnerships, manufacturing scale, and go-to-market differentiation in Crohn's therapeutics

Company-level strategies in Crohn's disease therapeutics reflect a mix of portfolio diversification, targeted R&D investment, and commercial partnerships. Leading biopharmaceutical organizations are concentrating on differentiated mechanisms such as selective interleukin modulation and gut-specific integrin blockade while investing in lifecycle strategies that include label expansions, formulation alternatives, and combination approaches. At the same time, mid-sized firms and specialized biotech companies are pursuing niche positioning through biomarker-driven development and precision medicine approaches to capture segments of the patient population with unmet needs.

Manufacturing scale and supply chain agility are increasingly central to competitive advantage, prompting strategic partnerships, contract manufacturing diversification, and regional footprint expansion. Commercial differentiation hinges on integrated services; companies that complement drug efficacy with patient support programs, hub services for specialty distribution, and digital adherence tools are better positioned to maintain persistence and reduce overall cost of care. In this evolving competitive landscape, partnerships and licensing deals can accelerate market entry and broaden clinical utility, while targeted M&A activity supports vertical integration where it bolsters supply security or accelerates access to proprietary technologies.

Practical and prioritized recommendations guiding clinical development, commercial execution, patient access, and supply resilience for Crohn's therapeutics

Leaders in the Crohn's therapeutics space should adopt a set of prioritized actions that align clinical development with commercial execution and patient access imperatives. First, design clinical programs that generate both robust efficacy endpoints and pragmatic real-world measures to satisfy regulators, payers, and clinicians; this dual focus improves the case for preferred placement in treatment algorithms. Second, optimize supply chains through geographic diversification and contractual resilience to reduce exposure to tariff-driven or geopolitical disruptions and to ensure continuity of care for patients on chronic therapy.

Third, develop comprehensive access strategies that combine value-based contracting with specialty pharmacy integration and digital patient support to maximize adherence and persistence. Fourth, tailor launch sequencing by channel and setting of care-recognizing that intravenous, subcutaneous, and oral modalities demand distinct operational approaches and reimbursement negotiations. Finally, invest selectively in companion diagnostics and biomarker research to support targeted use cases and to clear pathways for premium positioning where clinical differentiation is demonstrable. By prioritizing these actions, organizations can translate clinical promise into sustainable commercial performance while safeguarding patient access.

Comprehensive mixed-method research approach integrating expert interviews, systematic literature review, supply chain validation, and data triangulation

The research methodology underpinning this executive summary integrates multiple qualitative and quantitative approaches to ensure robust, replicable insights. Primary research included structured interviews with clinical thought leaders, payers, specialty pharmacists, and commercial leaders to capture frontline perspectives on therapeutic performance, adoption barriers, and reimbursement dynamics. These firsthand inputs were complemented by systematic review of peer-reviewed clinical literature, regulatory documentation, and guideline updates to validate mechanistic rationale and safety signals.

To strengthen reliability, the analysis incorporated supply chain validation through vendor mapping and distributor interviews, as well as triangulation across data sources to reconcile discrepancies and surface consistent patterns. Scenario analysis was used to stress-test strategic assumptions-particularly around tariff impacts, route-of-care shifts, and payer contracting innovations-so that recommendations reflect plausible operational contingencies. Finally, editorial synthesis prioritized clarity and actionable relevance for decision-makers, with transparent note of limitations where primary evidence is still evolving, thereby enabling informed use of the intelligence in strategic planning.

Conclusion synthesizing clinical, commercial, and policy implications for stakeholders aiming to advance therapeutic options and patient-centric care pathways

In conclusion, the Crohn's disease therapeutics landscape is characterized by rapid therapeutic innovation, evolving care delivery models, and shifting commercial dynamics that together demand strategic agility from industry and clinical stakeholders. Advances in biologic specificity and oral small molecules are expanding treatment options, but adoption will pivot on demonstrable real-world benefits, manageable safety profiles, and alignment with payer expectations. At the same time, external factors such as tariff policy changes and supply chain fragility add layers of operational risk that must be proactively managed.

Therefore, stakeholders should pursue an integrated approach that links clinical differentiation with pragmatic access strategies, resilient manufacturing and distribution, and evidence generation tailored for local health system needs. When executed thoughtfully, such an approach can accelerate appropriate patient access, support sustainable commercial returns, and foster innovation that meaningfully improves long-term patient outcomes. These synthesized implications provide a strategic foundation for teams seeking to navigate near-term disruptions while positioning for enduring success in Crohn's therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Impact of gut microbiome-targeted fecal microbiota transplant pipelines on Crohn's disease management outcomes in clinical practice
  • 5.2. Development and clinical trial progress of oral small-molecule S1P receptor modulators for moderate to severe Crohn's disease
  • 5.3. Adoption challenges and payer coverage landscape for high-cost biologic therapies in pediatric Crohn's disease populations
  • 5.4. Emerging role of personalized therapeutic drug monitoring using remote digital health platforms for Crohn's disease remission maintenance
  • 5.5. Strategic partnerships driving development of dual targeting anti-integrin and anti-TNF combination therapies in Crohn's disease

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Crohn's Disease Therapeutics Market, by Therapy Class

  • 8.1. Biologics
    • 8.1.1. Integrin Inhibitors
      • 8.1.1.1. Vedolizumab
    • 8.1.2. Interleukin Inhibitors
      • 8.1.2.1. Risankizumab
      • 8.1.2.2. Ustekinumab
    • 8.1.3. TNF Inhibitors
      • 8.1.3.1. Adalimumab
      • 8.1.3.2. Certolizumab
      • 8.1.3.3. Infliximab
  • 8.2. Immunosuppressants
    • 8.2.1. Methotrexate
    • 8.2.2. Thiopurines
      • 8.2.2.1. Azathioprine
      • 8.2.2.2. Mercaptopurine
  • 8.3. Small Molecules
    • 8.3.1. JAK Inhibitors
      • 8.3.1.1. Tofacitinib
      • 8.3.1.2. Upadacitinib

9. Crohn's Disease Therapeutics Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Crohn's Disease Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Retail Pharmacies
  • 10.3. Specialty Clinics

11. Crohn's Disease Therapeutics Market, by End User

  • 11.1. Home Care Settings
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Crohn's Disease Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Crohn's Disease Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Crohn's Disease Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. AbbVie Inc.
    • 15.3.2. Janssen Biotech, Inc.
    • 15.3.3. Takeda Pharmaceutical Company Limited
    • 15.3.4. F. Hoffmann-La Roche Ltd
    • 15.3.5. Pfizer Inc.
    • 15.3.6. Merck & Co., Inc.
    • 15.3.7. UCB S.A.
    • 15.3.8. Celltrion, Inc.
    • 15.3.9. Samsung Bioepis Co., Ltd.
    • 15.3.10. Sandoz International GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CROHN'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CROHN'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CROHN'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY VEDOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY VEDOLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY VEDOLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY VEDOLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY VEDOLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY VEDOLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TOFACITINIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TOFACITINIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TOFACITINIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TOFACITINIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TOFACITINIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TOFACITINIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY UPADACITINIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY UPADACITINIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY UPADACITINIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY UPADACITINIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY UPADACITINIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY UPADACITINIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPE